Compare PAVS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAVS | GLMD |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | Israel |
| Employees | 25 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.0M |
| IPO Year | 2018 | 2013 |
| Metric | PAVS | GLMD |
|---|---|---|
| Price | $0.07 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 36.4M | 305.4K |
| Earning Date | 07-31-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.41 |
| 52 Week High | $26.69 | $2.34 |
| Indicator | PAVS | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 44.46 |
| Support Level | N/A | $0.53 |
| Resistance Level | $1.68 | $0.69 |
| Average True Range (ATR) | 2.04 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 0.01 | 56.17 |
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.